



IFW  
USSN: 10/576,732  
Dkt. No.: PP021455.0004  
2300-21455

**PATENT**

**CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **October 25, 2006**.

10/25/2006  
Date

Michael A. Hobson  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:

MAGAGNOLI et al

Serial No.: 10/576,732

Filing Date: April 21, 2006

Title: STABILISED COMPOSITIONS

Examiner:

Group Art Unit:

Confirmation No.:

Customer No.: 27476

**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

Enclosed is an Information Disclosure Statement and accompanying Form  
PTO/SB/08A for the above-identified patent application.

- ☒ [X] In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ [ ] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
  - ☐ [ ] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
  - ☐ [ ] a statement as specified in 37 C.F.R. §1.97(e).
- ☐ [ ] In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.



USSN: 10/576,732  
Dkt. No.: PP021455.0004  
2300-21455

- ☐ Check No. \_\_\_\_ in the amount of \$\_\_\_\_ for the total fee is attached.
- ☒ A return receipt postcard is also enclosed.
- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 18-1648 for the total fee.  
This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: October 25, 2006

By: Jenny Buchbinder  
Jenny Buchbinder, Ph.D.  
Registration No. 48,588  
(650) 354-3383

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property - R440  
P. O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-8406  
Facsimile: (510) 655-3542



USSN: 10/576,732  
Dkt. No.: PP021455.0004  
2300-21455

**PATENT**

**CERTIFICATE OF MAILING PURSUANT TO 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **October 25, 2006**.

10/25/06  
Date

Michelle Hobson  
Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:	Examiner:
MAGAGNOLI et al.	Group Art Unit:
Serial No.: 10/576,732	Confirmation No.:
Filing Date: April 21, 2006	Customer No.: 27476
Title: STABILISED COMPOSTIONS	

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56,  
Applicant(s) hereby submits the following information in conformance with 37 C.F.R.  
§§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☐ No copy of the publication \_\_\_\_\_ listed on the attached Form PTO/SB/08A are being provided because the Office waives the requirement under 37 C.F.R. 1.98 (a) (2) (i) for submitting a copy of each cited U.S. patent and each U. S. patent application publication for all U.S. national patent applications filed after June 30, 2003.
- ☐ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application

Serial No. \_\_\_\_\_ to which the above-identified application  
claims priority under 35 U.S.C. §120.

- ☐ Publication(s) \_\_\_\_\_ listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to international application serial no. \_\_\_\_\_ and mailed on \_\_\_\_\_.
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. English language publication \_\_\_\_ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) \_\_\_\_\_ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) \_\_\_\_\_ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. \_\_\_\_\_.

This Information Disclosure Statement is filed within any one of the following time periods:


- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Respectfully submitted,

Date: October 25, 2006

By:   
Jenny Buchbinder, Ph.D.  
Registration No. 48,588  
(650) 354-3383

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property - R440  
P. O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-8406  
Facsimile: (510) 655-3542



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/576,732		
		Filing Date	April 21, 2006		
		First Named Inventor	Magagnoli		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	PP021455.0004 (2300-21455)


U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	AA	2002/044939 A1	04-18-2002	Pizza et al.	
	AB	4,816, 440	03-28-1989	Thomson	
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	BA	WO	02/101412	A2	12-19-2002	Maa et al.		<input type="checkbox"/>
	BB	WO	01/41800	A2	06-14-2001	Esikova et al.		<input type="checkbox"/>
	BC							<input type="checkbox"/>
	BD							<input type="checkbox"/>
	BE							<input type="checkbox"/>
	BF							<input type="checkbox"/>
	BG							<input type="checkbox"/>
	BH							<input type="checkbox"/>
	BI							<input type="checkbox"/>
	BJ							<input type="checkbox"/>
	BK							<input type="checkbox"/>
	BL							<input type="checkbox"/>
	BM							<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Examiner Signature	/Jennifer Graser/	Date Considered	07/13/2009
-----------------------	-------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

PTO/SB/08B (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<i>Application Number</i>	10/576,732		
		<i>Filing Date</i>	April 21, 2006		
		<i>First Named Inventor</i>	Magagnoli		
		<i>Art Unit</i>	Unassigned		
		<i>Examiner Name</i>	Unassigned		
Sheet	2	of	2	<i>Attorney Docket Number</i>	PP021455.0004 (2300-21455)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	PRONK et al. (1985) J. Biol. Chem. 260:13580-13584.	
	CB	MANNING et al. (1989) Pharm. Res. 6: 903-918.	
	CC	WANG et al. (1988) J. Parenteral Sci. Tech. 42: S3-S26.	
	CD	WANG (1999) Int. J. Pharm. 185: 129-188.	
	CE	WANG et al. (1980) J. Parenteral Drug Assoc. 34: 452-462.	
	CF		
	CG		
	CH		
	CI		
	CJ		
	CK		
	CL		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

<b>Examiner Signature</b>	<u>/Jennifer Graser/</u>	<b>Date Considered</b>	<u>07/13/2009</u>
-------------------------------	--------------------------	----------------------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.